Amylin Analogs Emerge as Next Major Weight Loss Therapy Class, Offering Clinically Meaningful Efficacy Standalone and in Combination

The global burden of obesity necessitates diverse therapeutic strategies beyond current incretin-based therapies, which, while transformative, do not address the full biological complexity of the disease for all patients. Amylin, a pancreatic peptide co-secreted with insulin, plays a crucial role in glucose homeostasis and appetite regulation by slowing gastric emptying, suppressing postprandial glucagon, and promoting satiety via central mechanisms. This multi-faceted action makes amylin a compelling target for novel weight loss interventions, aiming to fill existing treatment gaps and offer complementary pathways to existing therapies.

Researchers conducted a narrative review of amylin-based therapies either approved or in human clinical development for obesity as of April 30, 2026. The methodology involved comprehensive searches across PubMed/MEDLINE, ClinicalTrials.gov, and Google Scholar, supplemented by company press releases, investor reports, and major congress abstracts. The review aimed to synthesize preclinical and clinical evidence on amylin physiology and the emerging role of amylin analogs, including pramlintide, cagrilintide, eloralintide, petrelintide, MET-233i, ABBV-295, and AZD6234, as well as combination approaches like cagrilintide with semaglutide and zenagamtide.

Amylin's physiological actions were confirmed, demonstrating its ability to slow gastric emptying, suppress glucagon secretion, and induce meal termination through central nervous system mechanisms. Pramlintide, the first approved amylin analog, established the proof of concept for amylin-based therapies, albeit with modest efficacy and a frequent dosing regimen. The review highlighted a new generation of long-acting amylin analogs, including cagrilintide, eloralintide, petrelintide, MET-233i, ABBV-295, and AZD6234, which have demonstrated clinically meaningful weight loss. These newer compounds also exhibited generally favorable tolerability profiles across early-phase clinical trials. Furthermore, combination therapies, such as cagrilintide with the GLP-1 agonist semaglutide, and zenagamtide, showed enhanced efficacy, suggesting a synergistic effect from targeting multiple metabolic pathways.

The emergence of long-acting amylin analogs and combination therapies represents a significant advancement, offering clinically meaningful weight loss with favorable tolerability, moving beyond the limitations of first-generation compounds like pramlintide.